Literature DB >> 18591089

The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism.

W Birkmayer1, O Hornykiewicz.   

Abstract

Entities:  

Year:  1998        PMID： 18591089     DOI： 10.1016/s1353-8020(98)00013-3

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN： 1353-8020            Impact factor:   4.891


× No keyword cloud information.
  24 in total

Review 1.  Neuroproteomics as a promising tool in Parkinson's disease research.

Authors:  Ilse S Pienaar; William M U Daniels; Jürgen Götz
Journal:  J Neural Transm (Vienna)       Date:  2008-06-04       Impact factor: 3.575

2.  Twenty-first century brain banking: practical prerequisites and lessons from the past: the experience of New York Brain Bank, Taub Institute, Columbia University.

Authors:  Jean Paul G Vonsattel; Maria del Pilar Amaya; Etty Paola Cortes; Katerina Mancevska; Christian E Keller
Journal:  Cell Tissue Bank       Date:  2008-06-26       Impact factor: 1.522

3.  Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.

Authors:  Daniel Farré; Ana Muñoz; Estefanía Moreno; Irene Reyes-Resina; Júlia Canet-Pons; Iria G Dopeso-Reyes; Alberto J Rico; Carme Lluís; Josefa Mallol; Gemma Navarro; Enric I Canela; Antonio Cortés; José L Labandeira-García; Vicent Casadó; José L Lanciego; Rafael Franco
Journal:  Mol Neurobiol       Date:  2014-10-26       Impact factor: 5.590

Review 4.  Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

5.  Evidence for coupling between steady-state and dynamic extracellular dopamine concentrations in the rat striatum.

Authors:  Yuexiang Wang; Keith F Moquin; Adrian C Michael
Journal:  J Neurochem       Date:  2010-04-09       Impact factor: 5.372

Review 6.  Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

7.  Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.

Authors:  Vincenza Bagetta; Carmelo Sgobio; Valentina Pendolino; Giulia Del Papa; Alessandro Tozzi; Veronica Ghiglieri; Carmela Giampà; Elisa Zianni; Fabrizio Gardoni; Paolo Calabresi; Barbara Picconi
Journal:  J Neurosci       Date:  2012-12-05       Impact factor: 6.167

8.  Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption.

Authors:  Chun-Li Wang; Yang-Bin Fan; Hsiao-Hwa Lu; Tung-Hu Tsai; Ming-Cheng Tsai; Hui-Po Wang
Journal:  J Biomed Sci       Date:  2010-09-06       Impact factor: 8.410

Review 9.  Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

10.  Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat.

Authors:  Sinéad Walsh; Katarzyna Mnich; Ken Mackie; Adrienne M Gorman; David P Finn; Eilís Dowd
Journal:  Brain Res Bull       Date:  2010-01-25       Impact factor: 4.077
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.